Skip to main content
Erschienen in: Clinical Rheumatology 3/2007

01.03.2007 | Case Report

Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab

verfasst von: Alfonso Gutiérrez-Macías, Eva Lizarralde-Palacios, Pedro Martínez-Odriozola, Felipe Miguel-de la Villa

Erschienen in: Clinical Rheumatology | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

We present a case of tuberculous peritonitis in a 71-year-old woman with long-standing rheumatoid arthritis treated with adalimumab, and we review the association between antitumor necrosis factor therapy and tuberculosis. Our case illustrates that the index of suspicion of tuberculosis in these patients, even with atypical clinical features, must be very high, and underscores the need of tuberculosis screening before therapy is started.
Literatur
1.
2.
Zurück zum Zitat Bieber J, Kavanaugh A (2004) Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum Dis Clin North Am 30:257–270CrossRefPubMed Bieber J, Kavanaugh A (2004) Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum Dis Clin North Am 30:257–270CrossRefPubMed
3.
Zurück zum Zitat Rychly DJ, Dipiro JT (2005) Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25:1181–1192CrossRefPubMed Rychly DJ, Dipiro JT (2005) Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 25:1181–1192CrossRefPubMed
4.
5.
Zurück zum Zitat Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med 345:1098–1104CrossRefPubMed Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N Engl J Med 345:1098–1104CrossRefPubMed
6.
Zurück zum Zitat Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM (2004) Tuberculosis following the use of etarnecept, a tumor necrosis factor inhibitor. Clin Infect Dis 39:295–299CrossRefPubMed Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM (2004) Tuberculosis following the use of etarnecept, a tumor necrosis factor inhibitor. Clin Infect Dis 39:295–299CrossRefPubMed
7.
Zurück zum Zitat Wallis RS, Broder MS, Wong JY, Hanson ME, Beenouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265CrossRefPubMed Wallis RS, Broder MS, Wong JY, Hanson ME, Beenouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265CrossRefPubMed
8.
Zurück zum Zitat Carmona L, Hernández-García C, Vadillo C, Pato E, Balsa A, González-Alvaro I, EMECAR Study Group (2003) Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30:1436–1439PubMed Carmona L, Hernández-García C, Vadillo C, Pato E, Balsa A, González-Alvaro I, EMECAR Study Group (2003) Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 30:1436–1439PubMed
9.
Zurück zum Zitat Manadan AM, Block JA, Sequeira W (2003) Mycobacteria tuberculosis peritonitis associated with etarnecept therapy. Clin Exp Rheumatol 21:526PubMed Manadan AM, Block JA, Sequeira W (2003) Mycobacteria tuberculosis peritonitis associated with etarnecept therapy. Clin Exp Rheumatol 21:526PubMed
Metadaten
Titel
Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab
verfasst von
Alfonso Gutiérrez-Macías
Eva Lizarralde-Palacios
Pedro Martínez-Odriozola
Felipe Miguel-de la Villa
Publikationsdatum
01.03.2007
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 3/2007
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-0164-3

Weitere Artikel der Ausgabe 3/2007

Clinical Rheumatology 3/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.